Comparing Patient-Reported Outcomes of Exenatide and Insulin Glargine in Type 2 Diabetes
Author Information
Author(s): Secnik Boye Kristina, Matza Louis S, Oglesby Alan, Malley Karen, Kim Sunny, Hayes Risa P, Brodows Robert
Primary Institution: Eli Lilly and Company
Hypothesis
Are exenatide and insulin glargine comparable in terms of patient-reported outcomes?
Conclusion
Both exenatide and insulin glargine significantly improved patient-reported outcomes when added to oral medications for type 2 diabetes.
Supporting Evidence
- Both treatment groups showed significant improvements in patient-reported outcomes.
- Exenatide was associated with weight reduction, while insulin glargine was linked to weight gain.
- Patient satisfaction was comparable between both treatment groups despite differences in side effects.
Takeaway
This study looked at how two diabetes medications, exenatide and insulin glargine, made patients feel. Both helped patients feel better, even though they work a bit differently.
Methodology
Patients were randomized to receive either exenatide or insulin glargine for 26 weeks, with various patient-reported outcome measures assessed at baseline and endpoint.
Potential Biases
Potential bias due to the structured nature of the clinical trial compared to naturalistic settings.
Limitations
The study duration was relatively brief, and a larger sample size might have provided more statistical power.
Participant Demographics
The sample was primarily Caucasian (79.6%), with a mean age of 58.5 years and slightly more men (55.2%) than women.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website